Michael Singer, Partner

With 30 years of executive leadership, Michael Singer has significant operating, financial, investment, business/government and healthcare experience. In his career he has held positions as a Founding CEO of a medical technology company; the President of a substantial investment group; a CFO who took a private company public and then sold it; a Board member to several companies and organizations; an active private investor; and an investment banker specializing in Mergers & Acquisitions.  He has worked and lived in a variety of cities around the world, including London, Zurich, Brussels, New York, San Francisco, Seattle and Washington.

As Founding CEO of medical technology company BrainScope, Michael guided the company from technology development, clinical studies, product validation, Intellectual Property creation (100 patents), organizational build, and multiple (8) regulatory clearances to commercial launch of the first FDA-cleared medical device for assessment of the full spectrum of brain injury, including concussion. Working closely with the U.S. Food and Drug Administration (FDA) and the Department of Defense and using advanced AI techniques derived from multiple multi-site clinical studies, Michael led the company to such pathbreaking regulatory clearances as the “Concussion Index”, the “Brain Function Index”, and the “Structural Injury Classifier”. Michael also secured significant equity investment and research funding through government and military contracts. The benefit of this public-private partnership was detailed in the peer-reviewed Journal of Clinical and Translational Science.

Before Michael joined BrainScope, he was President of Revolution Health Investments, where he managed its sale to Everyday Health. He was previously the Chief Financial Officer, Executive Vice President of Corporate Development for Data Critical Corporation, a Seattle-based venture-backed medical device company. At Data Critical he was responsible for facilitating the company’s IPO and eventually led the sale of Data Critical to General Electric. He has also worked as an executive at Microsoft Corporation responsible for developing small business and healthcare strategies.  For a decade Michael was a healthcare investment banker and M&A generalist for Wolfensohn & Co., Alex. Brown and Montgomery Securities in New York and San Francisco. He started his career at Union Bank of Switzerland in Zurich.

Michael has served on the Board of Directors of Exact Sciences Corporation (NASDAQ: EXAS) (molecular diagnostics), MedEfficiency (medical devices, sold to Integra LifeSciences (NASDAQ: IART)), SparkPeople (consumer health), One Reel (entertainment), Data Critical Corporation (medical devices, sold to GE (NYSE: GE)), BrainScope (medical devices), and EpiWatch (digital health).  

Michael holds a Ph.D. from the London School of Economics.

Hal Walbrink, Partner

Hal Walbrink is a recognized leader in the medical  device space. In his current role as Founder/CEO of Xinetix Medical Product Development Hal assists early-stage companies in formation, product realization, and commercial launch of healthcare related product offerings.

 Xinetix has served 80+ companies in its 27-year history, resulting in combined annual product sales of over $1 billion and greater than $4 billion in strategic acquisition and IPO valuation. Hal has served as a medical technology and business expert in 37 legal cases involving patent infringement and product liability. He has testified before State, local, Federal courts, and the International Trade Commission. 

Hal has served 40+ years in roles ranging from Board Chairman to CXO, advisor, investor, and technical expert to over 100 companies. A formal education in Applied Physics coupled with broad executive experience in private, public, domestic, and international companies afford Hal a broad experience base to draw upon in leadership and advisory roles. He has deep domain knowledge and leadership experience in product conceptualization, development, and manufacturing. Additionally, he has had leadership responsibility for Regulatory Affairs, Intellectual Property, Marketing, Customer Service, and Operations for several medical device companies during his career.

Hal is a recognized technical expert in ultrasonics, microfluidics, fluid dynamics, thermal tissue modification, tissue cutting/coagulation/ablation, endoscopy, digital signal processing and operating room communication and control systems. His clinical experience includes Ophthalmology, Electrosurgery, Critical Care Respiratory Ventilation, Minimally Invasive Surgery, and General Surgery. Has been named inventor on nine issued US and International patents and numerous patent disclosures and applications.

Hal has a passion for giving back to the community. He is a mentor to recent college grads and participates in several healthcare industry network groups. He serves as an advisor to the Computer Science and Engineering School Leadership Council at the California State University, Fullerton and Mentor for the Bridge to Connect organization at the University of California, Irvine. Hal and his wife Teresa have served as Church Elders at Jubilee South Coast in Southern California and support and led missions’ trips to Zoe Ministry in Chang Mai, Thailand. Hal and Teresa are parents to five children and live in Laguna Niguel, California.

Muraarie Rajan, Partner

Muraarie Rajan has extensive experience in corporate strategy, investment banking, fundraising and investor relations. In his 30-year career he has held leadership positions in investment banking and industry. He has worked in London, New York, and India. 

Muraarie began his career at McKinsey & Company in New York. Subsequently, he spent over 15 years in investment banking beginning at Wolfensohn & Company, a boutique investment bank specializing in M&A and strategic advisory founded by James D. Wolfensohn (ninth President of the World Bank) and Paul Volcker (former Chairman of the Federal Reserve Board). He held subsequent senior positions at Credit Suisse, J.P. Morgan and Harmon & Co., culminating as a Managing Director and having led and executed M&A transactions in excess of $100 billion.

Returning to India, he joined Piramal Enterprises ($5 billion market capitalization) as the Executive Director responsible for mergers and acquisitions, corporate development, and investor relations. He was a Member of the Management Committee of Piramal Healthcare, a Member of the Group Executive Committee of Piramal Enterprises, and a Member of the Board of Directors of several companies. In his position he worked closely with the senior management team in identifying and executing transformational transactions for the Group both overseas and in India. He was actively involved in the sale of the domestic formulations business to Abbott ($3.7 billion) and the sale of Piramal Diagnostics (which was successfully turned around under his leadership as CEO) for $100 million to Fortis Healthcare. He also reshaped the investor relations function, attracting new well-reputed foreign institutional investors.

He then joined the JSW Group ($13 billion market capitalization) as the Executive Director responsible for the Group's mergers & acquisitions, capital raising, and investor relations and was a Member of the Group Executive Committee.

Subsequently, Muraarie has advised corporate clients on strategic transactions, most recently as the Principal Advisor to the Chairman of a publicly listed company where he was very involved in advising and executing transformational initiatives including leading the acquisition of a medical implants business in the U.S.

Muraarie holds an MBA from the MIT Sloan School of Management and completed his Chartered Accountancy in the UK.